Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M I Freed

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
European Journal of Clinical Pharmacology|June 22, 2001
The effect of acarbose on the pharmacokinetics of rosiglitazoneA K Miller, A M Inglis, K T Culkin, et al.
Diabetologia|April 18, 2000
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetesP Raskin, E B Rappaport, S T Cole, et al.
Diabetes Care|June 26, 2001
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetesP Raskin, M Rendell, M C Riddle, et al.
Journal of Clinical Pharmacology|November 15, 2000
Rosiglitazone does not alter the pharmacokinetics of metforminR A Di Cicco, A Allen, A Carr, et al.
Clinical Pharmacology and Therapeutics|May 20, 1998
A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy menB E Ilson, S C Boike, D E Martin, et al.
Clinical Pharmacology and Therapeutics|May 26, 1999
Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular toneM I Freed, D E Wilson, K A Thompson, et al.
Journal of Clinical Pharmacology|June 14, 2001
Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteersA M Inglis, A K Miller, K T Culkin, et al.
Journal of Clinical Pharmacology|February 1, 1997
Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitusD E Martin, G S DeCherney, B E Ilson, et al.
Journal of Clinical Pharmacology|December 1, 1994
Pharmacokinetics of famciclovir in subjects with chronic hepatic diseaseS C Boike, M Pue, P R Audet, et al.
Journal of Clinical Pharmacology|December 1, 1999
Rosiglitazone has no clinically significant effect on nifedipine pharmacokineticsR Z Harris, A M Inglis, A K Miller, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Pharmacology|June 22, 2001
The effect of acarbose on the pharmacokinetics of rosiglitazoneA K Miller, A M Inglis, K T Culkin, et al.
Diabetologia|April 18, 2000
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetesP Raskin, E B Rappaport, S T Cole, et al.
Diabetes Care|June 26, 2001
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetesP Raskin, M Rendell, M C Riddle, et al.
Journal of Clinical Pharmacology|November 15, 2000
Rosiglitazone does not alter the pharmacokinetics of metforminR A Di Cicco, A Allen, A Carr, et al.
Clinical Pharmacology and Therapeutics|May 20, 1998
A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy menB E Ilson, S C Boike, D E Martin, et al.
Clinical Pharmacology and Therapeutics|May 26, 1999
Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular toneM I Freed, D E Wilson, K A Thompson, et al.
Journal of Clinical Pharmacology|June 14, 2001
Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteersA M Inglis, A K Miller, K T Culkin, et al.
Journal of Clinical Pharmacology|February 1, 1997
Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitusD E Martin, G S DeCherney, B E Ilson, et al.
Journal of Clinical Pharmacology|December 1, 1994
Pharmacokinetics of famciclovir in subjects with chronic hepatic diseaseS C Boike, M Pue, P R Audet, et al.
Journal of Clinical Pharmacology|December 1, 1999
Rosiglitazone has no clinically significant effect on nifedipine pharmacokineticsR Z Harris, A M Inglis, A K Miller, et al.
Pageof 3